“…Signals from bioenergetics status, oxygen levels, DNA damage, and amino acids availability converge on mTOR, unleashing a series of metabolic responses [18]. In fact, it has been shown that mTOR, when incorporated in mTORC1, promotes the synthesis of proteins, lipids, and nucleotides, as well as the adoption of a glycolytic phenotype, and an increase of carbon flux in the pentose phosphate pathway [18,19]. Indeed, research efforts in the leukemia setting have been mainly focused on the glycolytic aspect, in an attempt to exploit this feature as a target for therapeutic intervention.…”